Post-authorisation Safety Cohort Observation Of Retacrit (tm) (Epoetin Zeta) Administered Subcutaneously For The Treatment Of Renal Anaemia (Pasco II)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 19 Mar 2018
At a glance
- Drugs Epoetin zeta (Primary)
- Indications Anaemia
- Focus Adverse reactions
- Acronyms PASCO II
- Sponsors Hospira; Pfizer
- 14 Mar 2018 Planned End Date changed from 30 Apr 2022 to 1 Apr 2022.
- 14 Mar 2018 Planned primary completion date changed from 30 Apr 2022 to 1 Apr 2022.
- 26 Feb 2018 Status changed from recruiting to active, no longer recruiting.